Clinical Trial

Personalised Multidisciplinary Treatment in Moderate to Severe IBS

Study acronym: Magont
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a 12-month longitudinal intervention study in adults (18-65 years) with moderate-severe IBS (IBS-SSS ≥175) evaluating a personalized, patient-centered multidisciplinary treatment delivered in a Swedish tertiary care setting. The program includes an internet-based IBS school followed by four evidence-based modules (physician-led medical management/education, dietician-led dietary intervention, psychologist-led IBS-focused behavioral therapy, and physiotherapy) delivered in a sequence chosen by the participant, with symptom evaluation after each module. Outcomes are assessed before and after treatment, with the primary endpoint defined as treatment response (IBS-SSS reduction ≥50 points), and secondary endpoints covering symptom/psychological measures, visceral sensitivity and biological stress plus gut biomarkers, and multimodal brain imaging (structural MRI, rs-fMRI, task fMRI, and insula MRS).
Trial Details
NCT Number NCT07534930
Lead Sponsor Linkoeping University
Collaborators: Ostergotland County Council, Sweden, The Kamprad Family Foundation for Entrepreneurship, Research & Charity
Conditions IBS (Irritable Bowel Syndrome), DGBI
Enrollment 150 participants
Start Date 2021-09-23
Primary Completion 2026-04-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-16